Welcome to our dedicated page for AMDOCS SEC filings (Ticker: DOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amdocs Limited SEC filings document the disclosures of a foreign private issuer that provides software and services to communications and media companies. Its Form 6-K reports include quarterly and annual financial materials, consolidated financial statements, operating and financial review, earnings presentations, and disclosures on equity activity and issuer purchases.
The filing record also covers shareholder meeting materials and voting results, including board elections, employee share purchase plan amendments, dividend program approvals, auditor ratification, and governance changes involving executive leadership and board composition. Registration-statement incorporation language connects selected Form 6-K reports to Amdocs' equity compensation filings on Form S-8.
Amdocs Limited reported first quarter fiscal 2026 revenue of $1.16 billion, up 4.1% year over year, or 3.5% in constant currency. GAAP diluted EPS rose to $1.45 from $1.33, while non-GAAP diluted EPS increased to $1.81 from $1.66.
The company highlighted a new multi-year strategic agreement with T-Mobile USA, an expanded multi-year engagement with Vodafone Germany, two new Western European customers, and the closing of the Matrixx Software acquisition. Amdocs also introduced aOS, an agentic operating system for telecommunications aimed at generative AI use cases.
Twelve-month backlog reached $4.25 billion, up about 2.7% from a year earlier, and free cash flow improved to $187.9 million from $78.2 million. For fiscal 2026, Amdocs guides to reported revenue growth of 1.5%-5.5%, constant-currency revenue growth of 1.0%-5.0%, GAAP diluted EPS growth of 10.0%-17.0%, non-GAAP diluted EPS growth of 4.0%-8.0%, and free cash flow of $710-$730 million.
Amdocs Limited held its 2026 Annual General Meeting, where shareholders elected ten directors to serve until the 2027 meeting, with each nominee receiving strong support. All management proposals on the agenda were approved.
Shareholders approved an amendment to the 2023 Employee Share Purchase Plan to add 2,200,000 ordinary shares reserved for issuance. They also increased the quarterly cash dividend rate from $0.527 per share to $0.569 per share.
In addition, shareholders approved the Company’s consolidated financial statements for the fiscal year ended September 30, 2025, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, authorizing the Audit Committee to set its remuneration.
Pzena Investment Management, LLC, a Delaware investment adviser, filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 12,195,663 shares of Amdocs Ltd common stock, representing 11.3% of the class as of the event date. Pzena reports sole power to vote or direct the vote over 9,871,510 shares and sole power to dispose or direct the disposition of 12,195,663 shares, with no shared voting or dispositive power.
The filing states that clients of the investment manager have the right to receive and the ultimate power to direct the receipt of dividends and sale proceeds for the reported securities, and that no single client’s interest relates to more than five percent of the class. Pzena certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Amdocs.
Amdocs Limited submitted a Form 6-K as a foreign private issuer to make its annual report for the year ended September 30, 2025 available to investors. The company states that this annual report is furnished as Exhibit 99.1 to the Form 6-K and clarifies that the information is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference into other Securities Act or Exchange Act filings.
Amdocs Limited has called its annual general meeting for January 30, 2026, asking shareholders to elect 10 incumbent directors and approve several key proposals. Shareholders are asked to amend the 2023 Employee Share Purchase Plan to add 2,200,000 ordinary shares, increasing the plan reserve to 4,600,000 shares, which the company notes is about 2% of the 107,949,539 ordinary shares outstanding as of December 2, 2025.
The agenda also includes raising the quarterly cash dividend from $0.527 to $0.569 per share, following years of strong cash generation and share repurchases of approximately $489.5 million, $563.1 million and $551.3 million in fiscal 2023, 2024 and 2025. Shareholders are further asked to approve the fiscal 2025 consolidated financial statements and ratify Ernst & Young LLP as independent auditor for fiscal 2026, with the audit committee authorized to set its fees.
Amdocs Limited files its Form 20‑F annual report for the fiscal year ended September 30, 2025, describing its communications‑focused software and services business and key risks.
The company reports 108,448,276 ordinary shares outstanding as of year‑end, net of treasury shares, and notes that additional ordinary shares are reserved for stock options and restricted stock units. Revenue is highly concentrated: AT&T provided 25.9% of revenue in fiscal 2025 and 24.5% in 2024, while T‑Mobile contributed 19.9% and 22.6%, and the ten largest customers together represented approximately 70% of revenue in both years. The report highlights exposure to global economic conditions, intense industry competition, rapid shifts such as 5G, cloud and GenAI, cybersecurity and data‑privacy threats, heavy reliance on skilled staff, integration risks from acquisitions and partnerships, and complex international, ESG and AI regulatory regimes that could affect operations and growth.
Amdocs Limited submitted a Form 6-K as a foreign private issuer to furnish information about its latest quarterly results. The company reports that it issued a press release on November 11, 2025 announcing financial results for the quarter ended September 30, 2025, and attached that release and an earnings presentation as Exhibits 99.1 and 99.2. Amdocs specifies that the information in this report, including the exhibits, is furnished rather than filed under U.S. securities laws, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities filings.
Amdocs Limited (DOX) Form 144 notice: The filing reports a proposed sale of 2,285 shares of Common Stock through Citigroup Global Markets, Inc. (broker address provided) on 09/02/2025. The aggregate market value of the shares to be sold is listed as $195,367.50 and the total number of shares outstanding is reported as 110,000,000. The securities were acquired on 09/02/2025 by a stock option exercise and sale from AMDOCS LIMITED, and the stated nature of payment is compensation. The filer affirms, by signature, that they are not aware of any undisclosed material adverse information about the issuer.
Amdocs Limited discloses selected note items from its consolidated financial statements. Accumulated other comprehensive income (loss) components as of June 30, 2025 and 2024 include an unrealized gain on derivatives, net of tax, of $33,285 (2025) versus $587 (2024); an unrealized loss on short-term interest-bearing investments, net of tax, of $(1,739) (2025) versus $(8,805) (2024); and an unrealized loss on defined benefit plan, net of tax, of $(2,209) (2025) versus $(2,392) (2024). The company reports net-of-tax amounts of $2,485 and $622 for the three months ended June 30, 2025 and 2024, respectively, and $2,295 and $1,844 for the nine months ended June 30, 2025 and 2024, respectively. Available-for-sale securities classification changed between periods: as of June 30, 2025, $75,154 were short-term interest-bearing investments and $20,230 were cash and cash equivalents; as of September 30, 2024, $168,242 were short-term interest-bearing investments and $142,920 were cash and cash equivalents. The company references new accounting guidance on expense disaggregation effective for fiscal 2028 (annual) and 2029 (interim) and is evaluating its impact. It notes distributions of earnings to noncontrolling interests starting fiscal 2023 and discloses share repurchase authorizations totaling $2.1 billion (adopted Aug 2, 2023 and May 7, 2025) with an aggregate unused authorization of $1.12 billion. Certain items (foreign tax detail) are referenced but not specified in the excerpt.
Janus Henderson Group plc reports beneficial ownership of 5,795,194 ordinary shares of Amdocs Limited, representing 5.2% of the class. The filing shows shared voting and shared dispositive power for that stake, and no sole voting or dispositive power. An indirect subsidiary (JHIUS) is identified as a deemed beneficial owner of 5,794,432 shares and the filing states certain indirect subsidiaries are registered investment advisers providing advice to Managed Portfolios. The filing certifies these holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.